Filing Flows › Ideaya Biosciences (IDYA) › Who owns the stock
Who owns Ideaya Biosciences (IDYA) stock
281 funds reported Ideaya Biosciences (IDYA) shares in their latest 13F filings, worth $4.2B in all. The largest holder is FMR LLC ($526M). Last quarter 140 funds added to their stakes and 114 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| FMR LLC | 14,109,431 | $526M | increase | 2026-06-30 |
| BlackRock | 8,893,260 | $331M | increase | 2026-06-30 |
| Jupiter Topco LLC | 8,579,881 | $320M | base | 2026-06-30 |
| Janus Henderson Group | 7,265,253 | $242M | increase | 2026-03-31 |
| Capital Research Global Investors | 5,344,701 | $199M | increase | 2026-06-30 |
| Baker Bros. Advisors LP | 5,010,030 | $187M | increase | 2026-06-30 |
| Vanguard Group | 5,019,324 | $174M | increase | 2025-12-31 |
| State Street | 4,548,911 | $170M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 4,132,646 | $154M | increase | 2026-06-30 |
| Logos Global Management LP | 3,000,000 | $112M | decrease | 2026-06-30 |
| Adage Capital Partners GP, L.L.C. | 2,715,391 | $101M | decrease | 2026-06-30 |
| Deerfield Management Company, L.P. (series C) | 2,714,503 | $101M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 2,425,602 | $90.4M | decrease | 2026-06-30 |
| Price T Rowe Associates | 2,207,451 | $82.3M | increase | 2026-06-30 |
| Morgan Stanley | 1,931,491 | $72.0M | increase | 2026-06-30 |
Ideaya Biosciences' latest quarter
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most IDYA stock?
By the latest 13F filings: FMR LLC ($526M); BlackRock ($331M); Jupiter Topco LLC ($320M); Janus Henderson Group ($242M); Capital Research Global Investors ($199M).
What is the short interest in IDYA?
9,079,434 shares were sold short at the 2026-10-15 settlement, -1.13% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.